Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Emgality is a prescription monoclonal antibody containing galcanezumab-gnlm. It is a calcitonin gene-related peptide antagonist approved in adults for preventive treatment of migraine and treatment of episodic cluster headache. The medicine is given by subcutaneous injection using indication-specific strengths and schedules.
read more about emgality ...Galcanezumab-gnlm binds to calcitonin gene-related peptide, commonly called CGRP, and blocks the ligand from binding to its receptor. CGRP signaling is involved in migraine and cluster headache biology. Blocking this pathway reduces CGRP receptor activation.
Emgality is approved for adults who need preventive migraine treatment and adults with episodic cluster headache. Current U.S. labeling does not establish safety and efficacy in pediatric patients. Migraine and cluster headache use different dose strengths and injection schedules.
For migraine prevention, treatment starts with 240 mg as two consecutive 120 mg injections, followed by 120 mg once monthly. For episodic cluster headache, 300 mg is given as three consecutive 100 mg injections at the start of the cluster period and then monthly until the cluster period ends.
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. Current labeling also warns about constipation with serious complications, new or worsening hypertension, and new or worsening Raynaud phenomenon. Injection-site reactions are the most common reactions reported in clinical studies.
Emgality prevents migraine and treats episodic cluster headache in adults.
The migraine regimen starts with 240 mg as two consecutive 120 mg subcutaneous injections.
After the loading dose, Emgality is injected at 120 mg once each month.
Yes. Current labeling warns about constipation with serious complications, including cases requiring hospitalization or surgery.
EMGALITY (Galcanezumab-gnlm) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33a147be-233a-40e8-a55e-e40936e28db0. Date Accessed September 29, 2026.
EMGALITY Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761063s010lbl.pdf. Date Accessed September 29, 2026.
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/29813147/. Date Accessed September 29, 2026.
Galcanezumab-gnlm Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a618063.html. Date Accessed September 29, 2026.
Galcanezumab in Chronic Migraine: The Randomized, Double-Blind, Placebo-Controlled REGAIN Study. https://pubmed.ncbi.nlm.nih.gov/30446596/. Date Accessed September 29, 2026.